

A person is running on a beach at sunset. The sun is low on the horizon, creating a warm, golden glow. The person is in the foreground, running towards the viewer. Their legs are in motion, and there is a splash of water or sand in the air around their feet. In the background, there are buildings and a body of water. The overall scene is dynamic and energetic.

Brighter

Interim information
January–September
2016.

Brighter AB (publ) 556736-8591

Interim information.

January 1–September 30, 2016.

- Operating income amounted to SEK 17,073 thousand (SEK 9,276 thousand).
- Profit after financial items amounted to SEK -9,908 thousand (SEK -6,435 thousand).
- Earnings per share before dilution SEK -0.22 (SEK -0.24).
- Earnings per share after dilution SEK -0.22 (SEK -0.24).

Significant events July to September 2016.

- 2016-08-26 – Brighter in final negotiations with mobile operators in Thailand and Indonesia.
- 2016-07-19 – Brighter's new share issue to repay its loans has now been registered.
- 2016-07-19 – Brighter's non-cash issue to acquire the company behind jDome® BikeAround™ has now been registered.
- 2016-07-07 – Brighter and Sanmina start working together to produce Actiste®.
- 2016-07-01 – Brighter and Telia sign an agreement for subscription services for the diabetes solution Actiste.

Significant events after the period.

- 2016-10-25 – Brighter merges its jDome business with Bestic® and plans a public listing as an independent company.
- 2016-10-12 – The Swedish Patent and Registration Office increases Brighter's patent protection.
- 2016-10-12 – Brighter wins arbitration case against former development partner.
- 2016-10-11 – Brighter carries out a private placement for SEK 11.2 million.
- 2016-10-04 – Brighter receives a breakthrough order for jDome BikeAround in Denmark.



A message from the CEO.

We are extremely happy with the third quarter of this year, as so many important events took place for Brighter. We have taken a major step forward into the production phase, laying a strong foundation for new and exciting partnerships in the future. We are particularly happy about finally having our first operator agreement in place; Telia is a company that has promoted digitalization in society for many years, and the company clearly shares our vision and ideas about how care will develop in the future. Starting to work with Telia marks an important milestone for Brighter. It means that we have a strong partner for the Swedish launch of Actiste in the second half of 2017. This is something we are now planning together.

Ericsson is already one of our strategic partners. In this quarter we worked together on a number of activities to develop our business; this included presenting Actiste at Ericsson's Digital Forum in Jakarta in the late summer. As one of our partners, Ericsson has also been involved in our ongoing negotiations for new potential collaborations.

Early in the quarter we were able to announce that Brighter had signed an agreement with Sanmina for the production of Actiste. The main reasons why we chose to work with Sanmina include the company's extensive experience of producing advanced medical devices, including devices for the diabetes segment, and their ISO 13485 certification. Sanmina's production capacity is also extremely flexible, which enables us to quickly scale up our process to handle some of the production locally on other markets if necessary and to exploit any synergies.

Our main focus over the past quarter has been to negotiate agreements with mobile operators in Indonesia and Thailand. Since November 2015, when we launched our Asian campaign, we've learned that it takes time to build relationships and business in the region and we are very proud to have been able to get this far in only one year. Our partnership with Ericsson is off course a key success factor and we expect to sign at least one agreement by the end of this year.

Thailand and Indonesia are two important markets that clearly need better diabetes care; the number of diabetics in Indonesia and Thailand is around 10 million and 4 million respectively; there is also an extremely high growth rate for the disease in the region. In Indonesia the number of diabetics has increased by around 6% annually, which can be compared with around 1% in Sweden. However, what is most striking is the fact that diabetes is growing in every part of the world. There has never been a greater need for or interest in better solutions.

What makes Thailand and Indonesia particularly interesting from a marketing point of view is the fact that these countries are implementing different kinds of national health plans, subsidies and insurance systems. This means that most people can receive care or are able to manage their disease effectively. There is also an ambition to introduce a harmonized regulatory system for medtech products throughout the region through the cooperation organization ASEAN (Association of Southeast Asian Nations). In the future this will make it easier for us



to continue to expand and spread Actiste in Southeast Asia.

Finally, I would like to introduce the new company Camanio Care, which is a merger of our activity tool jDome BikeAround and the robotics company Bestic. We merged these businesses in October, which has created a larger and stronger specialist company with a future focus. Although Brighter is a major owner of the company, we will not play an operational role in the business. Instead we are going to focus completely on launching Actiste for the diabetes market, while exploring new potential application areas where this product and our IP portfolio can create extra value.



Truls Sjöstedt, Founder and CEO of Brighter AB.





Brighter in brief.

Brighter develops solutions for data-driven and mobile healthcare. Thanks to its intellectual capital and innovative assistive devices, Actiste and jDome, the company is creating a more efficient care chain with the individual in focus. The aim is to simplify the information flow of relevant and reliable data between patient and care provider, and make it stronger and more efficient.

In the first instance, Brighter is investing in diabetes, but there will be opportunities moving forward to act on a general level that spans several diseases and care directions. This will be done via The Benefit Loop®, Brighter's cloud-based service that continuously gathers, processes and shares data on the user's terms.

The company is listed on NASDAQ OMX First North/BRIG.

For more information:

www.brighter.se

The Brighter offer.

Brighter develops products and services that meet a clear and easily identifiable user need in the care chain. The company is currently industrializing the diabetes aid Actiste, and the planning work for the launch is now underway. jDome BikeAround is an activity aid which is marketed and sold on different markets. Following the merger with Bestic, jDome will be marketed and sold through Camanio Care AB from now on.

The Benefit Loop.

The Benefit Loop is a cloud-based service that processes, analyzes and returns health data in the treatment chain from various connected tools and apps. It has been developed to package and visualize relevant information and send feedback to the user in a smart and user-friendly way. Brighter's vision is to promote behavioral change. This includes not only developing smart assistive devices, but also becoming a leading company in mobile health and data-driven healthcare. We can help to provide a clearer picture of an individual's health by making reliable readings continually available. The individual can also personally decide who, for example a clinic, relative or researcher, can be given access to the health data. The Benefit Loop puts the patient and the disease in focus and offers a number of benefits based on different functions and perspectives.

In the long term, our thinking is to pave the way for other suppliers to connect different types of instruments and apps to The Benefit Loop, as there are many other chronic diseases that have a similar need for monitoring and treatment that can take place remotely.

In addition, by opening up the platform to others, we can obtain more data that can be used to improve treatments, utilize care resources more efficiently, plan care better, develop better drugs and treatment methods, but above all, improve the quality of life for people who live with a chronic disease.



Treatment.

The treatment of chronic diseases, of which diabetes is one example, must be simple to monitor in order to avoid secondary diseases and suffering for patients and high costs for society. Providing a better picture of how the body responds makes it easier for the patient and healthcare to work together to achieve the treatment goals.

Logging.


By automatically logging as much information as possible, a continuous flow of correct data is created, which can be used by the patient's doctor or nurse to optimize and improve treatment.

Analysis.

The patient data readings that are automatically logged can be analyzed and used to adjust the treatment regimen or to justify a change in lifestyle. These readings can also be matched against the best methods of treatment and personal goals, which can optimize the treatment results and increase the quality of life in the future. By significantly increasing access to information, healthcare receives better data for treating and supporting the patient, while doctors can identify patterns and predict consequences.

Improvement.

Everyone involved in the care chain, i.e. the patient, care providers, society and other related parties such as the pharmaceutical industry, can benefit from being able to monitor patients and their disease. By getting feedback, it is possible to improve and check compliance with treatment, gain better supervision of medicines and their costs, and improve data and statistics on which the development of new drugs are based, which can increase the quality of the entire care chain.



Actiste.

Diabetes is a globally growing public health crisis. In [Sweden, around 450,000 people live with diabetes¹](#); in the Nordic countries, the corresponding figure is 1.5 million people and globally, there are an estimated 415 million diabetics. The International Diabetes Federation ([IDF](#)) forecasts that there will be up to 642 million diabetics by 2040. With today's medical products and well-controlled diabetes, diabetics can enjoy a good quality of life as well as a long life. However, the risks associated with increased blood sugar levels must be taken seriously, and in this respect healthcare and patients have a major responsibility to work together to avoid damage to blood vessels caused by high blood sugar levels.

Over time, excessively high blood sugar creates problems in different organs in the body, such as in the form of heart, vascular, kidney and eye complications.

There are also risks associated with overdosage of insulin and immediate complications caused by excessively low blood sugar levels (hypoglycemia).

To make it easier for diabetics to look after themselves and monitor their diabetes, we at Brighter are developing an integrated tool, Actiste, which is aimed at insulin-treated diabetes patients. Actiste enables patients to measure their blood sugar level and also to inject insulin if necessary. All values are automatically logged, both blood sugar levels and insulin doses, and can be sent via the integral Internet connection to the treating doctor and the clinic, which can then take steps to help the patient.

The launch of Actiste is approaching. We are currently in the industrialization phase, which includes manufacturing the tools, pre-production and CE-marking; our development team and production partner Sanmina are involved in this work.



After carefully evaluating different production alternatives, we have selected Sanmina as our manufacturing partner. Sanmina is a global Tier 1 supplier of integrated production solutions and has extensive experience of producing advanced medical devices, including millions of other diabetes tools. Other reasons that convinced us to choose Sanmina is the fact the company has extensive launch and manufacturing capacity both in Sweden and around the world, they have ISO 13485 certification, and they have the capacity to scale up the process.

Now that we have a reliable manufacturing partner and our first operator agreement with Telia for the Swedish market, the Actiste team can now turn its focus from the development phase to starting production. Work on producing a detailed launch plan for Actiste, focusing on Europe and Southeast Asia, is now fully underway.

In parallel with this development work, Brighter has commissioned focus groups that have given a very favorable response. An incredible 92% of participants in the focus groups say that Brighter has succeeded in making the process for diabetics much simpler and easier compared to existing equipment, which is significant confirmation that further reinforces our belief that Actiste will be beneficial when it is launched. The remaining 8% of the participants say that Brighter has made the process simpler and easier, which gives Actiste full marks – 100%.

¹ <http://www.diabetes.se/Diabetes/Om-diabetes/Diabetes-i-siffror> (in Swedish)



jDome BikeAround.

As average life expectancy continues to rise, the population of Sweden is become increasingly elderly. One consequence of an aging population is an increase in the number of people suffering from dementia. Although there are no exact statistics of the number of dementia sufferers in Sweden, the Swedish National Board of Health and Welfare estimates this figure to be around 160,000 people. Many of these people, along with the 88,000 or so Swedes who live in the 2,600 elderly care homes in Sweden, are dependent on meaningful activity.


Being able to offer meaningful activities and facilitating dialog about life and different memories between dementia patients, personnel and relatives are some of the biggest challenges for elderly care. This is the case not only for dementia sufferers but also everyone within elderly care, both in elderly accommodation and in day care centers.

With jDome BikeAround, users can cycle and navigate anywhere in the world with the aid of Google Street View, whose images are projected onto a surrounding screen.

When you use jDome BikeAround both the brain and body are stimulated, while at the same time users enjoy a social experience as they can talk about their childhood or other memories with personnel and relatives.

jDome BikeAround has received very positive feedback from users and a number of pilot projects were organized in Sweden in 2015. Experiences from a project in Västerås, Sweden, were published last autumn *in a*

Swedish Agency for Participation report *Welfare Technology and Environment Adaptations*. The report highlighted good examples from specific care homes and day care centers, which **included** jDome. The Swedish Agency for Participation has released another report *Technology Development within Healthcare and Care for Individuals with Cognitive Impairment of Decision-making Capacity*, which also recommends jDome.




The technical innovator John Nilsson is behind the concept of jDome BikeAround. His background is from the computer games industry. It is based on a computer connected to a projector, which projects images and films on a large screen that surrounds the viewer,



The Brighter market and business model.


Today there are more internet-connected things than people.
And yet, we have only scratched the surface.



50 %
of all Swedish households will be connected to healthcare systems within five years, according to Telia.

As our population is growing older, the need for improved healthcare increases.


Global population aged 60 years or over



Source: United nations Department of Public Information 2015

Diabetes: a global epidemic.

The number of diabetics in the world is increasing rapidly.



Sources: IDF Atlas 2015 & United Nations, Department of Economic and Social Affairs, Population Division 2015



Brighter AB (publ)

Norgegatan 2
SE-164 32 Kista
Sweden

+46 (0)8 550 088 20
info@brighter.se
www.brighter.se

Business and revenue model.

Brighter develops products and services that meet a clear user need in the care chain. The product Actiste and the cloud service The Benefit Loop are in the final phase of their development. jDome BikeAround is an activity aid which is being sold and marketed by Brighter on a number of different markets.

jDome BikeAround can either be bought or hired, and there is a range of add-on services available for the product through service agreements and supplementary agreements. Additional digital services for jDome (and Bestic) will be offered via The Benefit Loop.

Actiste is not going to be offered for sale separately, but will form part of a subscription service instead. The basic subscription will initially be targeted at the consumer market in order to quickly reach a broad market in several geographical areas. In the future this subscription will also be offered to the local parties that offer subsidies for this kind of equipment, such as private and state health insurance. Additional digital services will be offered to the end users and their relatives through The Benefit Loop.

The Benefit Loop.

The Benefit Loop from Brighter is the platform that will collate the data generated by users of different medical devices and “wearables”, including apps. Based on what the user decides, the collated data can be shared with different parties, such as relatives, doctors, nurses, home care services, insurance systems, pharmaceutical companies or other research and development centers. Users and their integrity are paramount to Brighter.

In the long term, Brighter intends to offer access to The Benefit Loop to all parties interested in offering connected medical devices to prevent them from having to develop their own platform.

The Benefit Loop plus user authorization will also create an opportunity to commercialize user data.

Actiste.

Although the focus markets for Actiste are initially Northern Europe and Asia, the company recognizes enormous potential in the rest of the world.

There are two arms to the Actiste business model: one aimed at consumers and the other at insurance systems, whether tax-financed (as in Sweden) or via private insurance. Actiste will be available through a monthly subscription, like a mobile phone contract where the phone is included. The subscription charge includes Actiste, testing sticks, needles, connection, data storage and a mobile app. Data storage and the app are included in The Benefit Loop as part of the subscription service.

One important component in the upcoming marketing of Actiste subscriptions involves signing agreements with mobile operators since Actiste is connected to the Internet. Brighter has signed its first agreement with Telia for subscription services for Actiste in the Swedish market. In addition to Sweden and Europe, focus will also be on Southeast Asia, specifically Thailand and Indonesia.



jDome BikeAround.

Although the focus markets for the jDome BikeAround are initially Sweden and the other Nordic countries, the company recognizes enormous potential in the rest of the world.

To date Brighter has concentrated on elderly care homes and day care centers that cater to elderly dementia sufferers. In February 2016, Brighter announced its intention to open up a new customer segment that includes personal care assistance providers and local authorities that work with people with disabilities who are entitled to disability support and service. Around 60,000 people in Sweden are entitled to such support, which means that Brighter feels this area offers enormous potential in Sweden.

The jDome BikeAround is sold directly by Brighter to local authorities and companies that provide care and via distributors on other markets. Brighter offers purchase, leasing and rental agreements for the jDome BikeAround. Support and upgrade services are also linked to the product itself.

We currently have three salespeople in Sweden, while sales in Denmark and Norway are managed by distributors.

In October, after the end of the period, Brighter announced that it was going to acquire Bestic AB through its subsidiary Brighter Two. Bestic AB is a Swedish robotics company that develops and sells products and assistive devices to healthcare and nursing. As a result of this acquisition, Brighter Two, which develops and sells jDome BikeAround, has merged with Bestic AB. Brighter Two also changed its name to Camanio Care AB. Camanio Care has recently carried out a new share issue and will be listed on a relevant marketplace in the first quarter of 2017. However, Brighter will continue to be one of the major joint owners in Camanio Care, even after the planned distribution of some of Brighter's shares in Camanio Care to Brighter's shareholders.



The shares.

Brighter AB (publ) is listed on NASDAQ OMX First North with the stock symbol BRIG. NASDAQ OMX First North is a Multilateral Trading Facility (MTF). As of September 30, 2016, 50,148,022 shares were issued. All shares have equal rights to company profits and assets.

The Brighter Certified Adviser on NASDAQ OMX First North is Remium Nordic AB.

Insider holdings.

Shares.	2015-09-30	Change	2016-09-30
Truls Sjöstedt – CEO	5,349,080	+ 331,910	5,680,990
Gert Westergren – Chair of the Board	505,386	+ 134,410	639,796
Henrik Norström – Deputy CEO	448,150	+ 151,301	599,451
John Nilsson – Creative Technology Director	0	+ 566,730	566,730
Lars Flening – Director	53,041	+ 159,798	212,839
Afsaneh Ghatan Bauer – Director	51,600	0	51,600
Sara Murby Forste – Director	20,480	+ 2,620	23,100
Jan Stålemark – Director	0	+ 18,670	18,670
Petra Kaur Ljungman – Director	11,780	+ 2,945	14,725
Nadezda Ershova – Head of QA/RA	10,997	- 5,108	5,889

Warrants.	2015-09-30	Change	2016-09-30
Truls Sjöstedt – CEO	875,993	+ 401,762	1,277,755
Henrik Norström – Deputy CEO	716,251	+ 1,071,834	1,788,085
Gert Westergren – Chair of the Board	690,709	- 404,214	286,495
Åsa Hallin Dahlberg	0	+ 200,000	200,000
Sara Murby Forste – Director	85,120	+ 97,380	182,500
Afsaneh Ghatan Bauer – Director	61,650	+ 70,000	131,650
Jan Stålemark – Director	55,000	+ 70,000	125,000
John Nilsson – Creative Technology Director	0	+ 30,000	30,000
Nadezda Ershova – Head of QA/RA	136,776	- 117,499	19,277
Petra Kaur Ljungman – Director	19,445	- 2,945	16,500
Lars Flening – Director	587,907	- 580,014	7,893



Income statement in SEK thousand (summary).

	2016-01-01 2016-09-30	2015-01-01 2015-09-30	2015-01-01 2015-12-31
Operating income	17,073	9,276	15,722
Capitalized production costs	16,924	9,217	15,601
Other income	150	59	121
Direct costs			
Other external costs	-22,100	-11,582	-21,169
Staff costs	-4,524	-3,784	-5,056
Depreciation, amortization and impairment	-142	-281	-903
Other costs	-124	-3	-11
Operating profit	-9,817	-6,374	-11,417
Profit from other items	-91	-61	-51
Profit after financial items	-9,908	-6,435	-11,468
Profit for the period	-9,908	-6,435	-11,468
Earnings per share, before dilution	-0.22	-0.24	-0.42
Earnings per share, after dilution	-0.22	-0.24	-0.42
Number of shares, before dilution	50,148,022	33,020,966	37,567,883
Number of shares, after dilution	55,648,022	41,348,295	44,584,101
Average number of shares, before dilution	45,679,036	26,798,035	27,010,391
Average number of shares, after dilution	51,179,036	35,125,364	34,026,609



Balance sheet in SEK thousand (summary).

	2016-09-30	2015-09-30	2015-12-31
ASSETS			
Capitalized expenditure	38,791	13,960	21,867
Patents and trademarks	2,707	2,582	2,214
Property, plant and equipment	363	503	485
Financial assets	16,032	250	13,244
Stocks	0	646	0
Total fixed assets	57,892	17,940	37,810
Short-term receivables	4,384	1,198	1,300
Cash at bank and in hand	1,972	5,243	720
Restricted funds	0	208	0
Total current assets	6,356	6,649	2,020
TOTAL ASSETS	64,248	24,590	39,830
EQUITY AND LIABILITIES			
Share capital	2,507	1,651	1,878
Share premium	99,241	55,618	67,228
Ongoing share issue	0	-3,092	0
Profit carried forward	-40,241	-27,979	-27,979
Projected profit	-9,908	-6,435	-11,468
Total equity	51,599	19,763	29,659
Long-term liabilities	6	0	0
Total long-term liabilities	6	0	0
Trade payables	4,924	3,970	7,039
Other liabilities*	6,418	54	1,997
Accruals and deferred income	1,301	803	1,136
Total current liabilities	12,642	4,827	10,172
TOTAL EQUITY AND LIABILITIES	64,248	24,590	39,831
PLEDGED ASSETS	2,208	2,208	2,208

*Includes loans (SEK 1.8 million) that were repaid in conjunction with the private placement that was registered after the end of the period and the capital adequacy guarantee for the subsidiary Brighter Two SEK 4.4 million).





We believe simplicity and access drive behavioral change.

Cash flow statement in SEK thousand (summary).

	2016-01-01 2016-06-30	2015-01-01 2015-06-30	2015-01-01 2015-12-31
Cash flow from operating activities before changes in working capital	-9,774	-6,154	-10,488
Changes in working capital			
Decrease/increase in current receivables	-3,084	-256	-358
Decrease/increase in current liabilities	-1,888	772	3,121
CASH FLOW FROM OPERATING ACTIVITIES	-14,746	-5,637	-7,725
Investment activities			
Acquisition of intangible fixed assets	-17,436	-8,030	-16,391
Acquisition of tangible fixed assets	0	0	-23
Acquisition of financial assets	-222	-200	-666
Changes in stock	0	-808	0
CASH FLOW FROM INVESTMENT ACTIVITIES	-17,658	-9,038	-17,080
Financing activities			
Loans raised/Amortized loans	1,800	0	6
New share issue (net after issue costs)	31,856	16,186	21,577
Client funds	0	-154	0
CASH FLOW FROM FINANCING ACTIVITIES	33,656	16,032	21,583
Cash flow for the period	1,251	1,510	-3,222
Opening cash and cash equivalents	720	3,942	3,942
CLOSING CASH AND CASH EQUIVALENTS	1,972	5,451	720



Accounting principles.

This interim information has been prepared in accordance with the Swedish Annual Accounts Act and the general advice of the Swedish Accounting Standards Board BFNAR 2012:1 Annual Report and Consolidated Financial Statements unless otherwise stated. Brighter AB (publ) is the parent company of a group, but does not prepare consolidated financial statements with reference to the exception rule in the Swedish Annual Accounts Act Chapter 7 Section 3 (smaller group).

With effect from the 2015 financial year, external charges for product development are included as capitalized production costs in the company's income statement. As a consequence of this, the figures from previous years have been adjusted. The effect of this adjustment has not had any effect on the company's performance and position other than affecting the classification of items in the income statement.

Dates for financial information.

Year-end report 2016: 2017-02-24

Interim information Jan-Mar 2017: 2017-04-24

Half-year report Jan-June 2017: 2017-08-25

Company audit.

This interim information has not been audited by the company's auditors.

Certified Adviser.

The Brighter Certified Adviser on NASDAQ OMX First North is Remium Nordic AB.

Submission of interim report.

Stockholm November 25, 2016

Brighter AB (publ).

The Board

For more information, please contact:

Truls Sjöstedt, CEO

Tel: +46 709 73 46 00


Email: truls.sjostedt@brighter.se

Henrik Norström, COO

Tel: +46 733 40 30 45

Email: henrik.norstrom@brighter.se



A full-page photograph of a person running on a beach at sunset. The person is in the center-right, running towards the left, splashing water. The background shows a beach, the ocean, and buildings in the distance under a warm, orange sky. The overall mood is energetic and vibrant.

Brighter AB (publ).

Corp. ID. 556736-8591

Norgegatan 2 4tr | SE-164 28 Kista | Sweden
tel: +46 8 55 00 88 20 | fax: +46 8 55 00 88 30

www.brighter.se